| Literature DB >> 23159924 |
Peng Cao1, Yong Liang, Xu Gao, Xiao-Ming Li, Zhen-Quan Song, Guobiao Liang.
Abstract
The 80% ethanol extract of Alstonia yunnanensis afforded five new monoterpenoid indole alkaloids: 11-hydroxy-6,7-epoxy-8-oxo-vincadifformine (1), 14-chloro-15-hydroxy- vincadifformine (2), perakine N(4)-oxide (3), raucaffrinoline N(4)-oxide (4), and vinorine N(1),N(4)-dioxide (5), together with three known compounds: 11-methoxy-6,7-epoxy-8-oxo- vincadifformine (6), vinorine N(4)-oxide (7) and vinorine (8). The structures of the isolated compounds were established based on 1D and 2D (1H-1H-COSY, HMQC, HMBC, and ROESY) NMR spectroscopy, in addition to high resolution mass spectrometry. The isolated compounds were tested in vitro for cytotoxic potential against seven tumor cell lines and anti-inflammatory activities. Compounds 3, 4 and 7 exhibited weak cytotoxicity against the tested cell lines and selective inhibition of Cox-2 (> 85%).Entities:
Mesh:
Substances:
Year: 2012 PMID: 23159924 PMCID: PMC6268798 DOI: 10.3390/molecules171113631
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The structures of compounds 1–8.
13C-NMR data of compounds 1–5 in CDCl3.
| No. | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| 2 | 166.5, s | 166.6, s | 179.7, s | 180.3, s | 147.4, s |
| 3 | 165.0, s | 54.6, t | 74.7, d | 74.6, d | 68.8, d |
| 5 | 43.6, t | 51.0, t | 67.0, d | 66.9, d | 67.6, d |
| 6 | 42.1, t | 44.3, t | 33.9, t | 33.8, t | 33.5, t |
| 7 | 56.8, s | 54.5, s | 65.5, s | 65.5, s | 58.4, s |
| 8 | 129.8, s | 137.9, s | 136.3, s | 136.5, s | 132.9, s |
| 9 | 122.0, d | 121.3, d | 125.6, d | 125.6, d | 126.2, d |
| 10 | 107.1, d | 120.4, d | 127.9, d | 127.8, d | 131.0, d |
| 11 | 156.5, s | 127.5, d | 130.4, d | 130.4, d | 1231.1, d |
| 12 | 97.8, d | 109.1, d | 122.2, d | 122.1, d | 116.2, d |
| 13 | 144.2, s | 143.1, s | 156.7, s | 156.6, s | 149.3, s |
| 14 | 51.2, d | 59.6, d | 26.7, t | 25.7, t | 28.5, t |
| 15 | 57.1, d | 76.0, d | 26.2, d | 26.6, d | 26.8, d |
| 16 | 89.0, s | 92.8, s | 50.8, d | 50.3, d | 49.1, d |
| 17 | 22.3, t | 26.8, t | 78.1, d | 78.0, d | 76.6, d |
| 18 | 7.3, q | 8.2, q | 201.6, d | 61.2, t | 12.7, q |
| 19 | 26.2, t | 22.9, t | 14.6, q | 15.1, q | 119.9, d |
| 20 | 40.7, s | 44.5, s | 51.2, d | 48.0, d | 131.1, s |
| 21 | 63.4, d | 69.7, d | 67.1, d | 67.6, d | 69.8, t |
| CO2 | 51.3, q | 51.2, q | 20.8, q | 20.2, q | 20.9, q |
| 168.3, s | 168.9, s | 171.6, s | 171.5, s | 171.5, s |
Figure 2Key HMBC () and 1H-1H-COSY () correlations of compound 1.
Figure 3Key HMBC (), 1H-1H-COSY (), and NOESY () correlations of compound 3.
Cytotoxicity of compounds 1–7 against seven human tumor cell lines a.
| Cell lines | |||||||
|---|---|---|---|---|---|---|---|
| BEN-MEN-1 | CCF-STTG1 | CHG-5 | SHG-44 | U251 | SK-MEL-2 | MCF-7 | |
| 1 | - | - | - | - | - | 95.5 | 91.2 |
| 2 | - | - | - | - | - | - | 97.6 |
| 3 | - | 12.3 | 12.9 | 11.8 | 12.3 | 33.7 | 28.1 |
| 4 | - | 11.4 | 12.1 | 9.2 | 9.7 | 34.9 | 29.9 |
| 5 | - | - | - | 58.3 | 71.8 | - | - |
| 6 | - | - | - | - | - | 93.7 | - |
| 7 | - | 16.7 | 15.8 | 17.4 | 14.9 | 35.5 | 31.2 |
| 8 | - | 67.1 | - | 64.2 | - | - | 76.2 |
| Adriamycin | 17.8 | 24.7 | 21.8 | 33.7 | 28.4 | 37.6 | 14.1 |
a Adriamycin are expressed as IC50 values in nM, and compound 1–7 are expressed as IC50 values in μM. (-) IC50 > 100 μM.
Evaluation of Anti-Inflammatory Activity of Compounds 1–8 a.
| COX-1 | COX-2 | |
|---|---|---|
| 27.35 | <0 | |
| <0 | <0 | |
| 43.21 | 94.77 | |
| 41.85 | 88.09 | |
| 38.21 | <0 | |
| 36.98 | <0 | |
| 41.32 | 94.05 | |
| 37.64 | <0 | |
| SC-560 | 63.20 | |
| NS-398 | 97.13 |
a Percent inhibition (all compounds and reference drugs concentration: 100 μM).
1H-NMR data of compounds 1–5 in CDCl3 (δ in ppm and J in Hz).
| No. | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| N1-H | 8.96 (s) | 8.94 (s) | - | - | - |
| 2 | - | - | - | - | |
| 3 | - | 3.29 (m) | 4.50 (d, 9.6) | 4.48 (d, 9.6) | 5.15 (d, 9.0) |
| 4 | - | - | - | - | - |
| 5 | 4.28 (dd, 6.6, 5.0) | 4.26 (dd, 6.6, 5.0) | 4.25 (dd, 6.6, 5.2) | ||
| 6a | 3.21, 4.44 (m) | 2.68, 2.98 (m) | 2.45 (d, 12.8) | 2.43 (d, 12.8) | 2.58 (d, 12.8) |
| 6b | 1.74, 2.02 (m) | 1.70, 2.11 (m) | 2.89 (m) | 2.87 (m) | 2.89 (dd, 12.8, 4.5) |
| 7 | - | - | - | - | - |
| 8 | - | - | - | - | - |
| 9 | 7.04 (d, 8.0) | 7.09 (d, 7.6) | 7.60 (d, 8.2) | 7.57 (d, 8.2) | 7.72 (d, 8.2) |
| 10 | 6.33 (dd, 8.0, 2.0) | 6.80 (dd, 7.6, 1.8) | 7.29 (dd, 8.2, 1.8) | 7.26 (dd, 8.2, 1.8) | 7.56 (dd, 8.2, 2.0) |
| 11 | - | 7.06 (dd, 7.6, 1.8) | 7.42 (dd, 8.2, 1.8) | 7.39 (dd, 8.2, 1.8) | 7.61 (dd, 8.2, 2.0) |
| 12 | 6.40 (d, 2.0) | 6.75 (d, 7.6) | 7.61 (d, 8.2) | 7.58 (d, 8.2) | 7.78 (d, 8.2) |
| 13 | - | - | - | - | - |
| 14a | 3.62 (d, 4.0) | 4.20 (m) | 2.05 (dd, 14.8,5.0) | 2.02 (dd, 14.8,5.0) | 2.10 (dd, 14.8, 5.2) |
| 14b | - | - | 2.58 (dd, 14.8, 9.6) | 2.56 (dd, 14.8, 9.6) | 2.43 (dd, 14.8, 9.0) |
| 15 | 3.48 (d, 4.0) | 3.92 (d, 6.2) | 2.71 (m) | 2.46 (m) | 3.37 (t, 5.2) |
| 16 | - | - | 3.06 (m) | 3.04 (m) | 2.76 (m) |
| 17 | 1.86, 2.68 (d, 15.8) | 2.72, 2.85 (d, 15.2) | 4.98 (d, 8.0) | 4.96 (d, 8.0) | 4.86 (d, 8.0) |
| 18 | 0.80 (t, 7.0) | 0.72 (t, 7.2) | 9.84 (s) | 3.37, 3.62 (m) | 1.70 (d, 7.2) |
| 19 | 1.10, 1.30 (m) | 0.92, 1.21 (m) | 1.52 (d, 6.6) | 1.48 (d, 6.6) | 5.45 (q, 7.2) |
| 20 | - | - | 2.87 (m) | 2.07 (m) | - |
| 21 | 3.63 (s) | 2.80 (s) | 3.96 (m) | 3.71 (m) | 4.03 (d, 14.2) |
| CO2 | 3.82 (s) | 3.80 (s) | 2.18 (s) | 2.15 (s) | 2.19 (s) |